February 12, 2014 /

ACT DMD Update with PTC (February 2014)

by: Parent Project Muscular Dystrophy

ACT DMD Update with PTC (February 2014)

On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD).

Research & Clinical Trial Webinars,

11 years ago

You may also like

NS Pharma's Exon 53 Skipping Program: Trial Recruitment & Update (February 2017)

NS Pharma’s Exon 53 Skipping Program: Trial Recruitment & Update (February 2017)

8 years ago

Research & Clinical Trial Webinars,

MoveDMD Trial: Catabasis Provides Update (February 2017)

MoveDMD Trial: Catabasis Provides Update (February 2017)

8 years ago

Research & Clinical Trial Webinars,

Mission DMD: FibroGen’s Anti-Fibrosis Program (February 2017)

Mission DMD: FibroGen’s Anti-Fibrosis Program (February 2017)

8 years ago

Research & Clinical Trial Webinars,

Summit's Utrophin Modulation Program (January 2017)

Summit’s Utrophin Modulation Program (January 2017)

8 years ago

Research & Clinical Trial Webinars,

Vamorolone (VBP15) Clinical Trials in Duchenne (January 2017)

Vamorolone (VBP15) Clinical Trials in Duchenne (January 2017)

8 years ago

Research & Clinical Trial Webinars,

A Closer Look at the Potential of CRISPR/Cas9 in Duchenne (December 2016)

A Closer Look at the Potential of CRISPR/Cas9 in Duchenne (December 2016)

9 years ago

Research & Clinical Trial Webinars,

NS Pharma's Exon 53 Skipping Program (November 2016)

NS Pharma’s Exon 53 Skipping Program (November 2016)

9 years ago

Research & Clinical Trial Webinars,

Community Update Call: Sarepta & Summit (October 2016)

Community Update Call: Sarepta & Summit (October 2016)

9 years ago

Research & Clinical Trial Webinars,

«1…19 202122 23…27 »

Page 21 of 27

Join Our Mailing List